Stocks · Health care · Biological Products, (No Diagnostic Substances)

REPLIGEN CORP

RGEN Clue Score51
United States Fiscal year ends December CIK 0000730272 Results filed 27 Oct 2026

What the insiders did No buying or selling

By person

15 insiders · 0 transactions
10.1×

Olivier Loeillot holds 10.1 times base salary in stock. $8.70M of shares against $860.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Olivier Loeillot last reported holding, valued at $190.00, the price Common Stock was last bought or sold at on the open market here, on 5 Oct 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Karen A Dawes
Director
—
—
—
92,816
$17.64M
+1.9%
Anthony Hunt
Director
—
—
—
89,062
$16.92M
−43.3%
Olivier Loeillot
Chief Executive Officer
—
—
—
45,788
$8.70M
+37.0%
Glenn P Muir
Director
—
—
—
40,051
$7.61M
+201.5%
James Bylund
Chief Operating Officer
—
—
—
25,423
$4.83M
+23.5%
Ralf Kuriyel
Senior VP, R&D
—
—
—
20,062
$3.81M
+63.3%
Jason K Garland
CFO
—
—
—
18,408
$3.50M
+128.9%
Brian Robb Douglass
Chief Product Officer
—
—
—
8,685
$1.65M
+38.9%
Martin D Madaus
Director
—
—
—
8,381
$1.59M
+81.7%
Violetta Hughes
Chief Accounting Officer
—
—
—
6,331
$1.20M
—
Manner Carrie Eglinton
Director
—
—
—
5,461
$1.04M
+56.3%
Nicolas Barthelemy
Director
—
—
—
5,436
$1.03M
+56.7%
Rohin Mhatre
Director
—
—
—
5,014
$952.66K
+64.6%
Konstantin Konstantinov
Director
—
—
—
3,889
$738.91K
+102.4%
Margaret Pax
Director
—
—
—
3,011
$572.09K
+279.7%

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.